Glycorex Transplantation AB — Investor Relations & Filings

Glycorex Transplantation AB is a medical technology company that has developed a proprietary technology platform for the specific removal of antibodies from blood. The technology is based on biologically active carbohydrates for extracorporeal blood treatment. Its flagship product, Glycosorb® ABO, is a single-use medical device that enables organ transplantation across the blood group barrier, primarily for kidney, liver, heart, and stem cell transplants. Used clinically since 2001, the product has facilitated over 6,000 ABO-incompatible transplants with documented long-term results comparable to blood group compatible procedures. The company is leveraging its core technology to expand into new applications, including a product for creating universal blood plasma for transfusions and developing novel treatments for autoimmune diseases, with an initial focus on rheumatoid arthritis.